Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Oct 7;2009(4):CD004562.
doi: 10.1002/14651858.CD004562.pub4.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women

Shom Goel  1 , Rohini Sharma, Anne Hamilton, Jane Beith
Affiliations
Meta-Analysis

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women

Shom Goel et al. Cochrane Database Syst Rev. .

Abstract

Background: Approximately 60% of breast cancers amongst premenopausal women express the nuclear oestrogen receptor (ER+ breast cancer). Adjuvant endocrine therapy is an integral component of care for ER+ breast cancer, exerting its effect by reducing the availability of oestrogen to micrometastatic tumour cells. Endocrine strategies in premenopausal women include oestrogen receptor blockade with tamoxifen, temporary suppression of ovarian oestrogen synthesis by luteinising hormone releasing hormone (LHRH) agonists, or permanent interruption of ovarian oestrogen synthesis with oophorectomy or radiotherapy. Aromatase inhibitors are also available with concurrent suppression of ovarian oestrogen synthesis, either through LHRH agonists, surgery, or radiotherapy. Chemotherapy can also have an endocrine action in premenopausal women by interrupting ovarian oestrogen production, either temporarily or permanently. International consensus statements recommend single agent tamoxifen as the current standard adjuvant endocrine therapy for premenopausal women (often preceded by chemotherapy), and the role of LHRH agonists remains under active investigation.

Objectives: To assess LHRH agonists as adjuvant therapy for women with early breast cancer.

Search strategy: The Cochrane Breast Cancer Group Specialised Register was searched on 19 February 2009. This register incorporates references from CENTRAL (The Cochrane Library) (to 2002), MEDLINE (1966 to July 2008), EMBASE (until 2002); and handsearches of abstracts from the San Antonio Breast Cancer Symposium, American Society of Clinical Oncology Annual Meeting, and the Clinical Oncological Society of Australia Annual Meeting. MEDLINE references (from August 2008 to 19th February 2009) were checked by the authors. The reference lists of related reviews were checked. A final check of the list of trials maintained by the Early Breast Cancer Trialists' Collaborative Group was made in January 2008.

Selection criteria: All randomised trials assessing LHRH agonists as adjuvant treatment in premenopausal women with early stage breast cancer were included. Specifically, we included trials that compared:(A) LHRH agonists (experimental arm) versus another treatment;(B) LHRH agonists + anti-oestrogen (experimental arm) versus another treatment;(C) LHRH agonists + chemotherapy (experimental arm) versus another treatment;(D) LHRH agonists + anti-oestrogen + chemotherapy (experimental arm) versus another treatment.

Data collection and analysis: Data were collected from trial reports. We reported estimates for the differences between treatments on recurrence free survival, overall survival, toxicity and quality of life using data available in the reports of each trial. Meta-analyses were not performed because of variability in the reporting of the trials.

Main results: We identified 14 randomised trials that involved over 13,000 premenopausal women with operable breast cancer, most of whom were ER+. The numbers of trials making the different comparisons were:(A) i. LHRH versus tamoxifen (three trials),ii. LHRH versus chemotherapy (four trials);(B) i. LHRH + tamoxifen versus tamoxifen (two trials),ii. LHRH + tamoxifen versus LHRH (three trials),iii. LHRH + tamoxifen versus chemotherapy (two trials),iv. LHRH + aromatase inhibitor versus LHRH + tamoxifen (one trial);(C) i. LHRH + chemotherapy versus LHRH (one trial),ii. LHRH + chemotherapy versus chemotherapy (five trials);(D) LHRH + tamoxifen + chemotherapy versus chemotherapy (three trials).The LHRH agonist in most of these trials was goserelin.For most of the treatment comparisons there are too few trials, too few randomised patients, or too little follow up to draw reliable estimates of the relative effects of different treatments.(A) LHRH monotherapy: results suggest that adjuvant LHRH agonist monotherapy is similar to older chemotherapy protocols (eg. CMF) in terms of recurrence-free and overall survival in ER+ patients. There are insufficient data to compare LHRH agonist monotherapy to tamoxifen alone, but available results suggest that these treatments are comparable in terms of recurrence-free survival.(B) LHRH + anti-oestrogen therapy: there are insufficient data to compare the combination of an LHRH agonist plus tamoxifen to tamoxifen alone. Results suggest that the LHRH agonist plus tamoxifen combination may be superior to an LHRH agonist alone or to chemotherapy alone, but the chemotherapy protocols tested are outdated. The data comparing LHRH agonists plus aromatase inhibitors to LHRH agonists plus tamoxifen are currently inconclusive.(C) LHRH + chemotherapy: there are insufficient data to compare the LHRH + chemotherapy combination to an LHRH agonist alone, although results from a single study suggest comparable efficacy in ER+ patients. There is a trend towards improved recurrence-free and overall survival in patients who received an LHRH agonist plus chemotherapy combination in comparison to chemotherapy alone.(D) LHRH agonist + chemotherapy + tamoxifen: there is a trend towards improved recurrence-free and overall survival in patients who received an LHRH agonist plus tamoxifen plus chemotherapy in comparison to chemotherapy alone.There are insufficient data to assess the effect of the addition of LHRH agonists to the current standard treatment of chemotherapy plus tamoxifen.Endocrine therapy with LHRH agonists appears to have fewer side-effects than the forms of chemotherapy assessed. The optimal duration of LHRH therapy in the adjuvant setting is unclear.

Authors' conclusions: Overall, the data from currently published clinical trials of LHRH agonists in the adjuvant setting for premenopausal women with endocrine-sensitive breast cancer are supportive of clinical benefit. Nonetheless, definitive comparisons against current clinical standards of care that include third generation chemotherapy regimens and tamoxifen are required before their place in the adjuvant setting can be properly defined. The authors conclude that the current data strongly support the continuation of current trials that definitively compare a variety of combinations of LHRH agonists and anti-oestrogenic strategies to the current standard of five years of tamoxifen.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

References

References to studies included in this review

ABCSG‐12 {published data only}
    1. Gnant M, Mlineritsch B, Schippinger W, Luschin‐Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert, M, Hubalek M, Bjelic‐Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. New England Journal of Medicine 2009;360:679‐91. - PubMed
ABCSG 5 {published data only}
    1. Gnant M, Greil R, Kubista E, et al. The impact of treatment‐induced amenorrhea on survival of premenopausal patients with endocrine‐responsive breast cancer: 10‐year results of ABCSG‐05 (CMF vs. goserelin+tamoxifen). Breast Cancer Research and Treatment 2006;100 Suppl 1:10‐1 (abstract 17).
    1. Jakesz R, Hausmaninger H, Kubista E, et al. Randomised adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in pre‐menopausal patients with hormone responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group trial 5. Journal of Clinical Oncology 2002;20:4621‐7. - PubMed
ECOG 5188 INT‐0101 {published data only}
    1. Davidson N, O’Neil A, Vukov A, et al. Effect of chemohormonal therapy in pre‐menopausal, node (+), receptor (+) breast cancer: an eastern cooperative oncology group phase III Intergroup trial (E5188, INT‐0101). Proceedings of the American Society of Clinical Oncology. 2003:5 (abstract 15).
    1. Davidson NE, O'Neill AM, Vukov AM, Osborne K, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node–positive, steroid hormone receptor–positive breast cancer: Results from INT 0101 (E5188). Journal of Clinical Oncology 2005;23(25):5973‐82. - PubMed
FASG 06 {published data only}
    1. Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus chemotherapy in pre‐menopausal early‐stage breast cancer patients (pts) with positive hormone‐receptor (HR+) and 1–3 node‐positive (N+) tumor: results of the FASG 06 trial. Proceedings of the American Society of Clinical Oncology. 2000:72a (abstract 279).
    1. Roche H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, et al. Complete hormonal blockade versus epirubicin‐based chemotherapy in premenopausal, one to three node‐ positive, and hormone‐receptor positive, early breast cancer patients: 7‐year follow‐up results of French Adjuvant Study Group 06 randomised trial. Annals of Oncology 2006;17:1221‐7. - PubMed
GABG IV‐A‐93 {published data only}
    1. Minckwitz G, Graf E, Geberth M, et al. Goserelin versus CMF as adjuvant therapy for node‐negative, hormone receptor‐positive breast cancer in premenopausal women. The GABG trial IV‐A‐93 Trial. Proceedings of the American Society of Clinical Oncology. 2004:11s (abstract 534).
    1. Minckwitz G, Graf E, Geberth M, Eiermannd W, Jonate W, Conradf B, et al. CMF versus goserelin as adjuvant therapy for node‐negative, hormone‐receptor‐positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV‐A‐93). European Journal of Cancer 2006;42:1780‐8. - PubMed
    1. Minckwitz G, de Assesn A, Conrad B, et al. Medical ovarian ablation versus polychemotherapy in premenopausal women with node‐negative, receptor positive breast cancer. The ongoing trial 'A‐93' of the German Adjuvant Greast Cancer Group (GABG). Proceedings of the American Society of Clinical Oncology. 1999:(abstract 395).
GABG IV‐B‐93 {published data only}
    1. Kaufmann M, Graf E, Jonat W, et al. Goserelin versus control after adjuvant, risk adapted chemotherapy in premenopausal women with breast cancer. GABG trial IV‐B‐93. Proceedings of the American Society of Clinical Oncology. 2004:24s (abstract 588).
    1. Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberthf M, et al. for the German Adjuvant Breast Cancer Study Group (GABG). A randomised trial of goserelin versus control after adjuvant, risk‐adapted chemotherapy in premenopausal patients with primary breast cancer – GABG‐IV B‐93. European Journal of Cancer 2007;43:2351‐8. - PubMed
IBCSG VIII {published data only}
    1. Bernhard J, Zahrieh D, Castiglione‐Gertsch M, et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients: the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology 2007;25:263‐70. - PubMed
    1. Castiglione‐Gertsch M, O’Neill A, Gelber RD, et al. Is the addition of adjuvant chemotherapy always necessary in node negative (N‐) pre/perimenopausal breast cancer patients (pts) who receive goserelin?: first results of IBCSG trial VIII. Proceedings of the American Society of Clinical Oncology. 2001:38a (abstract 149).
    1. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node‐negative breast cancer: a randomized trial. Journal of the National Cancer Institute 2003;95:1833‐46. - PubMed
MAM 01 GOCSI {published data only}
    1. Bianco AR, Costanzo R, Lorenzo G, et al. The MAM‐1 GOCSI trial: a randomised trial with factorial design of chemo‐endocrine adjuvant treatment in node positive (N+) early breast cancer (ebc). Proceedings of the American Society of Clinical Oncology. 2001:27a (abstract 104).
    1. Placido S, Laurentiis M, Lena M, et al. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node‐positive breast cancer. British Journal of Cancer 2005;92:467‐74. - PMC - PubMed
Pretoria {published data only}
    1. Falkson CI, Falkson HC, Falkson G. The effect of chemotherapy with or without GnHRA on serum hormone levels in premenopausal women with breast cancer. Proceedings of the American Society of Clinical Oncology. 1990:(abstract 90).
    1. Falkson CI, Jooste R, Falkson HC, et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) plus or minus depo‐buserelin in pre‐menopausal women with lymph node positive breast cancer. Proceedings of the American Society of Clinical Oncology. 2001:7b (abstract 1777).
Soreide 2002 {published data only}
    1. Soreide JA, Varhaug JE, Fjosne HE, et al. Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre‐menopausal patients with operable node positive stage II breast cancer. A prospective randomised national multicenter study. European Journal of Surgical Oncology 2002;28:505‐10. - PubMed
TABLE {published data only}
    1. Schmid P, Untch M, Kosse V, Bondar G, Vassiljev L, Tarutinov V, et al. Leuprorelin acetate every‐3‐months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node‐positive breast cancer: The TABLE Study. Journal of Clinical Oncology 2007;25(18):2509‐15. - PubMed
    1. Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node positive, premenopausal breast cancer patients: preliminary results of the TABLE‐study (Takeda Adjuvant Breast Cancer Study with Leuprorelin acetate). Anticancer Research 2002;22:2325‐32. - PubMed
    1. Untch M, Kahlert S, Kosse V, et al. LHRH‐analogue therapy with leuprorelin‐acetate three‐month depot offers similar efficacy to conventional adjuvant CMF chemotherapy in receptor positive, node positive breast cancer patients. San Antonio Breast Cancer Symposium. 2003:(abstract 40).
ZBCSG Trial B {published data only}
    1. Mitsuyama S, Nomura Y, Ohno S, et al. Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan ‐ Zoladex Breast Cancer Study Group Trial‐B [Japanese]. Japanese Journal of Cancer Chemotherapy 2005;32:2071‐7. - PubMed
ZEBRA {published data only}
    1. Jonat W, Kaufman M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in pre‐menopausal patients with node‐positive breast cancer: the Zoladex Early Breast Cancer Research Association study. Journal of Clinical Oncology 2002;20:4628‐35. - PubMed
    1. Kaufmann Ma, Jonat W, Blameyc R, Cuzick J, Namere M, Fogelman I, et al. on behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group. Survival analyses from the ZEBRA study: goserelin (ZoladexTM) versus CMF in premenopausal women with node‐positive breast cancer. European Journal of Cancer 2003;39:1711‐7. - PubMed
    1. Haes H, Olschewski M, Kaufman M, et al. Quality of life in goserelin‐treated versus cyclophosphamide + methotrexate + fluorouracil‐treated premenopausal and perimenopausal patients with node‐positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. Journal of Clinical Oncology 2003;21:4510‐6. - PubMed
ZIPP {published data only}
    1. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre‐menopausal patients with early breast cancer: Results from the ZIPP study. European Journal of Cancer 2006;42:895‐904. - PubMed
    1. Baum M, Houghton J, Sawyer W, et al. Management of pre‐menopausal women with early breast cancer: is there a role for goserelin?. Proceedings of the American Society of Clinical Oncology. 2001:38a (abstract 103).
    1. Nystedt M, Berglund G, Bolund C, et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomised study. Journal of Clinical Oncology 2003;21:1836‐44. - PubMed

References to studies excluded from this review

ABCTCG study {published data only}
    1. Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. Journal of the National Cancer Institute 2007;99:516‐25. - PubMed
Arriagada 2005 {published data only}
    1. Arriagada R, Le M, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 pre‐menopausal patients with early breast cancer treated with adjuvant chemotherapy. Annals of Oncology 2005;16:389‐96. - PubMed
Grocta 02 {published data only}
    1. Boccardio F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of oestrogen receptor‐positive pre‐/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomised trial.. Journal of Clinical Oncology 2000;18:2718‐27. - PubMed
    1. Boccardo F, Rubagotti A, Amoroso D, et al. CMF versus tamoxifen (TAM) plus goserelin (GOS) as adjuvant treatment of ER positive )ER+) pre‐perimenopausal breast cancer (CA) patients (PTS). Preliminary results of the GROCTA 02 study. Proceedings of the American Sociey of Clinical Oncology. 1998:abstract 382.
    1. Boccardo F, Rubagotti A, Amoroso D, et al. CMF versus tamoxifen plus gosereline as adjuvant treatment of ER‐positive pre‐perimenopausal breast cancer patients: preliminary results of an ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) trial. Adjuvant Therapy of Cancer VIII. Philadelphia: Lippincott‐Raven, 1997:101‐8.
INT 0142 {published data only}
    1. Robert NJ, Wang M, Cella D, Martino S, Tripathy D, Ingle J, et al. Phase III comparison of tamoxifen versus tamoxifen and ovarian abation in premenopausal women with axillary node‐negative receptor=positive breast cancer < 3cm. Proceedings of the American Society of Clinical Oncology 2003;22:5a.

References to ongoing studies

IBCSG TEXT {published data only}
    1. IBCSG TEXT. Ongoing study August 2003.
PERCHE {published data only}
    1. IBCSG PERCHE. Ongoing study August 2003.
SOFT {published data only}
    1. IBCSG SOFT. Ongoing study August 2003.
UKCCR {published data only}
    1. UKCCR. Ongoing study Starting date of trial not provided. Contact author for more information.

Additional references

Baum 2006
    1. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre‐menopausal patients with early breast cancer: Results from the ZIPP study. European Journal of Cancer 2006;42:895‐904. - PubMed
Bernhard 2007
    1. Bernhard J, Zahrieh D, Castiglione‐Gertsch M, et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients: the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology 2007;25:263‐70. - PubMed
Bines 1996
    1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in pre menopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 1998;14:1718‐29. - PubMed
Cuzick 2006
    1. Cuzick J, on behalf of the LHRH‐Agonist Overview Group. The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomised trials. Breast Cancer Research and Treatment 2006;100 Suppl 1:10 (abstract 15).
Davidson 2003
    1. Davidson NE, O'Neill A, Vukov A, Osborne CK, Martino S, White D, et al. Chemohormonal therapy in premenopausal node‐positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT‐0101). Proceedings of the American Society of Clinical Oncology. 2003. - PubMed
de Haes 2003
    1. Haes H, Olschewski M, Kaufman M, et al. Quality of life in goserelin‐treated versus cyclophosphamide + methotrexate + fluorouracil‐treated premenopausal and perimenopausal patients with node‐positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. Journal of Clinical Oncology 2003;21:4510‐6. - PubMed
EBCTCG 1996
    1. Early Breast Cancer Trialists' Collaborative Group. Ovarian oblation in early breast cancer: Overview of the randomised trials. Lancet 1998;348:1189‐96. - PubMed
EBCTCG 2003
    1. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation for Early Breast Cancer (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000485] - DOI
EBCTCG 2005
    1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials. Lancet 2005;365:1687‐717. - PubMed
Ejlertsen 1999
    1. Ejlertsen B, Dombernowsky P, Mouridsen HT, Kamby C, Kjaer M, Pose C, et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proceedings of the American Society of Clinical Oncology 1999;18:66a.
Forward 2004
    1. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second‐line endocrine therapy for premenopausal advanced breast cancer. British Journal of Cancer 2004;90:590‐4. - PMC - PubMed
Furr 1989
    1. Furr BJA. Pharmacology of the luteinising hormone releasing hormone (LHRH) analog "Zoladex". Hormonal Research 1989;32 Suppl 1:86‐92. - PubMed
Gelber 1996
    1. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta‐analysis of quality adjusted survival. Lancet 1996;347:1066‐71. - PubMed
Higgins 2008
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.. Available from www.cochrane‐handbook.org.
Jemal 2008
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 2008;58(2):71‐96. - PubMed
Klijn 2001
    1. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta‐analysis of four randomised trials. Journal of Clinical Oncology 2001;19:343‐53. - PubMed
LHRH‐Agonists 2007
    1. LHRH‐Agonists in early Breast Cancer Overview Group. Use of luteinising‐hormone‐releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone‐receptor‐positive breast cancer: a meta‐analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711‐23. - PubMed
Liddle 1996
    1. Liddle J, Irwig L. Method for evaluating research and guideline evidence. Sydney: NSW Health Department, 1996.
Pagani 1998
    1. Pagani O, O'Neil A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. European Journal of Cancer 1998;34:632‐40. - PubMed
Parmar 1998
    1. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34. - PubMed
Pujol 1998
    1. Pujol P, Daures JP, Thezenas S, et al. Changing estrogen and progesterone receptor patterns in breast cancer carcinoma during the menstrual cycle and menopause. Cancer 1998;83:698‐705. - PubMed
SCTBG and ICRF 1993
    1. Scottish Cancer Trials Breast Group (SCTBG) and ICRF Breast Unit Guys Hospital London. Adjuvant ovarian ablation versus CMF in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993;341:1293‐9. - PubMed
Taylor 1998
    1. Taylor CW, Green S, Dalton WS, et al. Multi centre randomised clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor‐positive metastatic breast cancer: An intergroup study. Journal of Clinical Oncology 1998;16:994‐9. - PubMed
Walshe 2006
    1. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 2006;24:5769‐79. - PubMed
Williams 2006
    1. Williams C, Brunskill S, Altman D, et al. Cost‐effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment 2006;10(34):1‐204. - PubMed
Yusuf 1985
    1. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in cardiovascular disease 1985;5:335‐71. - PubMed

References to other published versions of this review

Sharma 2005
    1. Sharma R, Beith J, Hamilton A. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer. The Breast 2005;14:181‐91. - PubMed